Related Experiment Video
Updated: Sep 16, 2025

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
Transcription Factors and Methods for the Pharmacological Correction of Their Activity
Svetlana V Guryanova1,2, Tatiana V Maksimova2, Madina M Azova2
1M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Abstract:
Transcription factors (TFs) are proteins that control gene expression by binding to specific DNA sequences and are essential for cell development, differentiation, and homeostasis. Dysregulation of TFs is implicated in numerous diseases, including cancer, autoimmune disorders, and neurodegeneration. While TFs were traditionally considered "undruggable" due to their lack of well-defined binding pockets, recent advances have made it possible to modulate their activity using diverse pharmacological strategies. Major TF families include NF-κB, p53, STATs, HIF-1α, AP-1, Nrf2, and nuclear hormone receptors, which take part in the regulation of inflammation, tumor suppression, cytokine signaling, hypoxia and stress response, oxidative stress, and hormonal response, respectively. TFs can perform multiple functions, participating in the regulation of opposing processes depending on the context. NF-κB, for instance, plays dual roles in immunity and cancer, and is targeted by proteasome and IKKβ inhibitors. p53, often mutated in cancer, is reactivated using MDM2 antagonist Nutlin-3, refunctionalizing compound APR-246, or stapled peptides. HIF-1α, which regulates hypoxic responses and angiogenesis, is inhibited by agents like acriflavine or stabilized in anemia therapies by HIF-PHD inhibitor roxadustat. STATs, especially STAT3 and STAT5, are oncogenic and targeted via JAK inhibitors or novel PROTAC degraders, for instance SD-36. AP-1, implicated in cancer and arthritis, can be inhibited by T-5224 or kinase inhibitors JNK and p38 MAPK. Nrf2, a key antioxidant regulator, can be activated by agents like DMF or inhibited in chemoresistant tumors. Pharmacological strategies include direct inhibitors, activators, PROTACs, molecular glues, and epigenetic modulators. Challenges remain, including the structural inaccessibility of TFs, functional redundancy, off-target effects, and delivery barriers. Despite these challenges, transcription factor modulation is emerging as a viable and promising therapeutic approach, with ongoing research focusing on specificity, safety, and efficient delivery methods to realize its full clinical potential.
Insights
Transcription factors (TFs) are crucial for gene expression and cell function. New strategies are emerging to target TFs for treating diseases like cancer, despite challenges in drug development.
Area of Science:
- Molecular Biology
- Pharmacology
- Genetics
Background:
- Transcription factors (TFs) regulate gene expression and are vital for cellular processes.
- Dysregulated TFs are linked to diseases such as cancer, autoimmune disorders, and neurodegeneration.
- Historically considered undruggable, TFs are now targets for novel therapeutic interventions.
Purpose of the Study:
- To review current pharmacological strategies for modulating transcription factor activity.
- To highlight key transcription factor families and their roles in disease.
- To discuss challenges and future directions in TF-targeted therapies.
Main Methods:
- Review of existing literature on transcription factor biology and pharmacology.
- Analysis of major transcription factor families (NF-κB, p53, STATs, HIF-1α, AP-1, Nrf2) and their therapeutic targeting.
- Categorization of pharmacological strategies, including inhibitors, activators, PROTACs, and epigenetic modulators.
Main Results:
- Several TF families (NF-κB, p53, STATs, HIF-1α, AP-1, Nrf2) are implicated in various diseases and have specific inhibitors or activators.
- Diverse pharmacological approaches are being developed, including small molecule inhibitors, activators, PROTACs, molecular glues, and epigenetic modifiers.
- Examples of targeted TFs and their associated drugs include NF-κB inhibitors, p53 reactivators (Nutlin-3, APR-246), HIF-1α inhibitors/stabilizers (acriflavine, roxadustat), STAT inhibitors (JAK inhibitors, SD-36), AP-1 inhibitors (T-5224), and Nrf2 modulators.
Conclusions:
- Transcription factor modulation represents a promising therapeutic avenue for numerous diseases.
- Overcoming challenges like structural inaccessibility, off-target effects, and delivery is crucial for clinical success.
- Continued research focusing on specificity, safety, and efficient delivery will unlock the full potential of TF-targeted therapies.
Related Concept Videos
Transcription Factors
General Transcription Factors
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Co-activators and Co-repressors
Methods of Nuclear Reprogramming

